CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 11 enrolled
Drug / intervention
Ropidoxuridine +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02993146
NCT02993146Phase 1Active
CompareCT.gov

Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

National Cancer Institute (NCI)·interventional·Posted Dec 15, 2016·Updated Apr 30, 2026

In Brief

A Phase 1 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacological Study, and 3 other interventions for Hematopoietic and Lymphoid Cell Neoplasm and 2 related conditions. Active but no longer recruiting, targeting 11 participants across 14 sites.

Detailed Summary

This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
CountriesUnited States
Collaborators--

Timeline

Phase 1Active
20172018201920202021202220232024202520262027
First PostedDec 15, 2016
Enrollment StartMay 8, 2017
Primary CompletionAug 19, 2022
Study CompletionOct 3, 2026
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.5 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies

Quality-of-Life Assessmentother

Ancillary studies

Ropidoxuridinedrug

Given PO

Whole-Brain Radiotherapyradiation

Undergo WBRT